Back to Search
Start Over
Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC)
- Source :
- Journal of Clinical Oncology. 36:104-104
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- 104Background: Combining immune-checkpoint inhibitors with chemotherapy yielded high response rates in patients (pts) with metastatic TNBC. Therefore, we evaluated the addition of durvalumab, an an...
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
Durvalumab
Taxane
Anthracycline
business.industry
medicine.medical_treatment
Neoadjuvant Study
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
bacteria
In patient
business
Triple-negative breast cancer
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........62cdf0d33638e40898dab5169de78b02
- Full Text :
- https://doi.org/10.1200/jco.2018.36.15_suppl.104